{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:18:16Z","timestamp":1788049096567,"version":"build-2784847793"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22577117"],"award-info":[{"award-number":["22577117"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejmech.2026.119169","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:21:03Z","timestamp":1784301663000},"page":"119169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Dual-acting molecular hybrid strategy: A dopamine D2 receptor agonist with synergistic anti-ferroptosis activity for the treatment of Parkinson's disease"],"prefix":"10.1016","volume":"318","author":[{"given":"Qi","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"En","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Ohuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosei","family":"Funamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisaka","family":"Kurita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongping","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Inden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9366-3679","authenticated-orcid":false,"given":"Wenteng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119169_bib1","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41573-022-00390-x","article-title":"Function and therapeutic value of astrocytes in neurological diseases","volume":"21","author":"Lee","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119169_bib2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41582-022-00618-9","article-title":"Multimodal brain and retinal imaging of dopaminergic degeneration in Parkinson disease","volume":"18","author":"Lee","year":"2022","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ejmech.2026.119169_bib3","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41401-020-0365-y","article-title":"Recent advances in dopaminergic strategies for the treatment of Parkinson's disease","volume":"41","author":"Mao","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2026.119169_bib4","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1212\/WNL.0000000000012868","article-title":"Dopaminergic therapy for motor symptoms in early parkinson disease practice guideline summary: a report of the AAN guideline subcommittee","volume":"97","author":"Pringsheim","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.ejmech.2026.119169_bib5","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.drudis.2018.01.033","article-title":"Safinamide: a new hope for Parkinson's disease?","volume":"23","author":"Teixeira","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2026.119169_bib6","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2165\/00003088-200039040-00001","article-title":"Clinical pharmacokinetics of ropinirole","volume":"39","author":"Kaye","year":"2000","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2026.119169_bib7","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2165\/00023210-200519110-00006","article-title":"Rotigotine: in parkinson's disease","volume":"19","author":"Reynolds","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejmech.2026.119169_bib8","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.pharmthera.2010.06.002","article-title":"From the cell to the clinic: a comparative review of the partial D2\/D3 receptor agonist and \u03b12-adrenoceptor antagonist, piribedil, in the treatment of parkinson's disease","volume":"128","author":"Millan","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2026.119169_bib9","first-page":"1980","article-title":"A review on therapeutic strategies against Parkinson's disease: current trends and future perspectives","volume":"24","author":"Papagiouvannis","year":"2024","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119169_bib10","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3390\/antiox14040396","article-title":"Evaluation of additive neuroprotective effect of combination therapy for Parkinson's disease using in vitro models","volume":"14","author":"Shtilbans","year":"2025","journal-title":"Antioxidants"},{"key":"10.1016\/j.ejmech.2026.119169_bib11","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1136\/jnnp-2019-322042","article-title":"Brain iron deposition is linked with cognitive severity in parkinson's disease","volume":"91","author":"Thomas","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ejmech.2026.119169_bib12","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1093\/brain\/awab191","article-title":"The spatiotemporal changes in dopamine, neuromelanin and iron characterizing parkinson's disease","volume":"144","author":"Biondetti","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.ejmech.2026.119169_bib13","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: an iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.119169_bib14","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.molmed.2022.02.003","article-title":"Ferroptosis in Parkinson's disease: glia-neuron crosstalk","volume":"28","author":"Wang","year":"2022","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ejmech.2026.119169_bib15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.freeradbiomed.2020.03.015","article-title":"Ferroptosis was more initial in cell death caused by iron overload and its underlying mechanism in parkinson's disease","volume":"152","author":"Zhang","year":"2020","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ejmech.2026.119169_bib16","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1089\/ars.2013.5593","article-title":"Targeting chelatable iron as a therapeutic modality in Parkinson's disease","volume":"21","author":"Devos","year":"2014","journal-title":"Antioxidants Redox Signal."},{"key":"10.1016\/j.ejmech.2026.119169_bib17","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1021\/acschemneuro.7b00478","article-title":"Mechanism underlying the effectiveness of deferiprone in alleviating Parkinson's disease symptoms","volume":"9","author":"Sun","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2026.119169_bib18","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1111\/j.1471-4159.2008.05332.x","article-title":"Neuroprotective actions of deferiprone in cultured cortical neurons and SHSY-5Y cells","volume":"105","author":"Molina-Holgado","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejmech.2026.119169_bib19","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00702-010-0531-3","article-title":"Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration","volume":"118","author":"Dexter","year":"2011","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.ejmech.2026.119169_bib20","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41598-017-01402-2","article-title":"Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease","volume":"7","author":"Martin-Bastida","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.119169_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cmet.2024.07.013","article-title":"Integrative clinical and preclinical studies identify FerroTerminator1 as a potent therapeutic drug for MASH","volume":"36","author":"Tao","year":"2024","journal-title":"Cell Metab."},{"key":"10.1016\/j.ejmech.2026.119169_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115933","article-title":"Synthesis and structure-activity optimization of hydroxypyridinones against rhabdomyolysis-induced acute kidney injury","volume":"263","author":"Cen","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119169_bib23","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1021\/acschembio.2c00914","article-title":"Targeting labile iron-mediated ferroptosis provides a potential therapeutic strategy for rhabdomyolysis-induced acute kidney injury","volume":"18","author":"Zhu","year":"2023","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119169_bib24","doi-asserted-by":"crossref","first-page":"3646","DOI":"10.1021\/acschemneuro.0c00557","article-title":"Effectiveness of the iron chelator CN128 in mitigating the formation of dopamine oxidation products associated the progression of Parkinson's disease","volume":"11","author":"Sun","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2026.119169_bib25","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/s41422-023-00808-0","article-title":"Structural genomics of the human dopamine receptor system","volume":"33","author":"Xu","year":"2023","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2026.119169_bib26","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0163-7258(94)90041-8","article-title":"Dopamine receptors: molecular biology, biochemistry and behavioural aspects","volume":"64","author":"Jackson","year":"1994","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.ejmech.2026.119169_bib27","article-title":"Quantifiable and inexpensive cell-free fluorescent method to confirm the ability of novel compounds to chelate iron","volume":"204","author":"Carter","year":"2024","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.ejmech.2026.119169_bib28","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/mds.10447","article-title":"Models of parkinson's disease","volume":"18","author":"Orth","year":"2003","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejmech.2026.119169_bib29","article-title":"Targeting ferroptosis in parkinson's disease: mechanisms and emerging therapeutic strategies","volume":"23","author":"Zhou","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119169_bib30","article-title":"Ferroptosis in parkinson's disease: a review of molecular mechanisms and emerging therapeutic strategies","volume":"20","author":"Wang","year":"2026","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.ejmech.2026.119169_bib31","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1186\/s12967-024-05740-4","article-title":"The role of mitochondria in iron overload-induced damage","volume":"22","author":"Zhao","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ejmech.2026.119169_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107886","article-title":"Modeling secondary iron overload cardiomyopathy with human induced pluripotent stem cell-derived cardiomyocytes","volume":"32","author":"Rhee","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2026.119169_bib33","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1254\/jphs.SC0060098","article-title":"Distribution of DJ-1, Parkinson's disease-related protein PARK7, and its alteration in 6-hydroxydopamine-treated hemiparkinsonian rat brain","volume":"102","author":"Yanagida","year":"2006","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2026.119169_bib34","doi-asserted-by":"crossref","first-page":"W5","DOI":"10.1093\/nar\/gkab255","article-title":"ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties","volume":"49","author":"Xiong","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2026.119169_bib35","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1021\/ci600292q","article-title":"Prediction of pH-dependent aqueous solubility of druglike molecules","volume":"46","author":"Hansen","year":"2006","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2026.119169_bib36","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0223-5234(03)00012-6","article-title":"High throughput artificial membrane permeability assay for blood-brain barrier","volume":"38","author":"Di","year":"2003","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119169_bib37","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1126\/science.6823561","volume":"4587","author":"Langston","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.119169_bib38","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.neulet.2007.12.001","article-title":"Neuroprotective effects of rotigotine in the acute MPTP-Lesioned mouse model of Parkinson's disease","volume":"432","author":"Scheller","year":"2008","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejmech.2026.119169_bib39","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/jps.2600820217","article-title":"Pharmacokinetics of the dopamine D2 agonist S(-)-2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin in freely moving rats","volume":"82","author":"Swart","year":"1993","journal-title":"J. Pharmaceut. Sci."},{"key":"10.1016\/j.ejmech.2026.119169_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111484","article-title":"Kaempferol has potent protective and antifibrillogenic effects for \u03b1-synuclein neurotoxicity in vitro","volume":"22","author":"Inden","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119169_bib41","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/j.1471-4159.2005.03413.x","article-title":"Serofendic acid prevents 6-hydroxydopamine-induced nigral neurodegeneration and drug-induced rotational asymmetry in hemi-parkinsonian rats","volume":"95","author":"Inden","year":"2005","journal-title":"J. Neurochem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426006148?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426006148?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:14:13Z","timestamp":1788048853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426006148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":41,"alternative-id":["S0223523426006148"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119169","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual-acting molecular hybrid strategy: A dopamine D2 receptor agonist with synergistic anti-ferroptosis activity for the treatment of Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119169","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119169"}}